Cargando…
Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry
OBJECTIVES: To evaluate long-term effectiveness of natalizumab (NTZ) and to determine demographic, clinical, and radiological predictors regarding long-term disease activity (≥ 7 years) in a nationwide observational cohort, using data collected prospectively in a real-life setting. MATERIALS AND MET...
Autores principales: | Guger, Michael, Enzinger, Christian, Leutmezer, Fritz, Di Pauli, Franziska, Kraus, Jörg, Kalcher, Stefan, Kvas, Erich, Berger, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505366/ https://www.ncbi.nlm.nih.gov/pubmed/33890167 http://dx.doi.org/10.1007/s00415-021-10559-w |
Ejemplares similares
-
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023) -
Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing–remitting multiple sclerosis in Austria
por: Guger, Michael, et al.
Publicado: (2023) -
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023) -
Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
por: Guger, Michael, et al.
Publicado: (2020) -
Oral therapies for treatment of relapsing–remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method
por: Guger, Michael, et al.
Publicado: (2020)